Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

Richard D. Kim • 2 Jul 2020
ESMO WCGIC 2020
Bile Duct Cancer Gastrointestinal Cancer 5-fluorouracil Antibodies Capecitabine Trametinib
SWOG S1310

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, outlines results from a Phase II trial evaluating single agent MEK inhibitor trametinib versus 5-fluorouracil (5-FU) or capecitabine in refractory advanced biliary cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Richard D. Kim

2:15
The role of immunotherapy in cholangiocarcinoma
Richard D. Kim et al. • 26 Jan 2023
2:40
Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer
Richard D. Kim et al. • 26 Jan 2023
1:55
The latest in targeted therapies for advanced colorectal cancer
Richard D. Kim et al. • 26 Jan 2023
2:44
Biomarkers of treatment response in patients with MMR-proficient CRC
Richard D. Kim et al. • 26 Jan 2023

Related Videos

2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
1:28
Evolving biomarker driven therapies to overcome gastric cancer tumor resistance
Yelena Janjigian • 8 Apr 2024
0:56
Adjuvant chemotherapy in biliary tract cancer post-tumor resection
Olatunji Alese • 8 Apr 2024
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals